KEYNOTE-522 (ClinicalTrials.gov, NCT03036488), is a randomized, double-blind Phase 3 trial. The dual primary endpoints were pCR rate, defined as pathological stage ypT0/Tis ypN0 at the time of definitive surgery, and event-free sur...
Peter Schmid, MD, PhD, discusses the background, methods, and design of the phase 3 KEYNOTE-522 trial. This is a modal window. The Playback API request failed for an unknown reason Error Code: VIDEO_CLOUD_ERR_UNKNOWN Technical details : Unknown catalog request error. Session ID: 2025-...
However, the KEYNOTE 522 trial has demonstrated improved outcomes with the incorporation of the PD-1 inhibitor Pembrolizumab alongside neoadjuvant chemotherapy.Methods:A retrospective cohort analysis of 106 patients treated with the KEYNOTE 522 regimen within Cleveland Clinic from January 2020 to July ...
KEYNOTE-522是免疫检查点抑制剂用于早期三阴性乳腺癌新辅助治疗入组病例最多的一项研究,与多数类似早期三阴性乳腺癌研究不同的是,研究组不仅在新辅助化疗时联合应用帕博利珠单抗,而且在术后辅助治疗时继续应用,前后共一年。本研究的重要意义在于...
KEYNOTE-522是一项随机双盲III期临床试验,评估早期TNBC患者中帕博利珠单抗+新辅助化疗与单纯新辅助化疗后,分别接受帕博利珠单抗或安慰剂辅助治疗的疗效和安全性。主要终点是病理完全缓解率(pCR,ypT0/Tis ypN0)和无事件生存期(EFS)。该研究共纳入了1174名患者,以2:1的比例随机分为帕博利珠单抗+化疗组和安慰剂+化疗...
The KEYNOTE-522 trial is the first randomised phase 3 trial of an immune checkpoint inhibitor in early triple negative breast cancer. We've seen data in metastatic triple negative breast cancer with immune checkpoint inhibitors showing a clear benefit in survival. When it comes to early triple ...
Clinical trial identification NCT03036488. Editorial acknowledgement Medical writing and/or editorial assistance was provided by Christine McCrary Sisk. This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Legal entity responsible for the...
KEYNOTE-522 是首个在高危早期 TNBC 患者中表现出 EFS 积极结果的免疫治疗研究。证明了在早期 TNBC 患者中,无论 PD-L1 状态如何,与单独化疗相比,帕博利珠单抗联合化疗作为新辅助治疗的 pCR 在统计学上显著增加,在术后继续作为单药...
Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at the 2024 ESMO Congress. Peter Schmid, MD, PhD, of Barts Cancer Institute at Queen Mary University in London, United Kingdom, discusses his key takeaways from the ...
KEYNOTE-522 (NCT03036488) is a phase III study of neoadjuvant pembro + chemo followed by adjuvant pembro vs neoadjuvant placebo + chemo followed by adjuvant placebo in pts with TNBC. Trial design: Eligible pts are aged ≥18 y with previously untreated, centrally confirmed, nonmetastatic TNBC, ...